Anti-Cancer Agents and Biological Therapy
Clinical Pharmacology of Anti-Cancer Agents
Oncological Emergencies
Latest ESMO videos
Featured medwireNews
Durvalumab Addition Boosts Advanced Biliary Tract Cancer Survival
KRYSTAL-1: Adagrasib Demonstrates Activity Against Pancreatic, GI cancers
Lenvatinib–Pembrolizumab Boost Advanced Endometrial Cancer Survival
Mosunetuzumab offers high response rates in relapsed or refractory follicular lymphoma
Isatuximab Boosts MRD Negativity When Added to Standard Care for Newly Diagnosed Multiple Myeloma
E-Learning
ESMO E-Learning: PARP Inhibitors: Past, Present and Future
ESMO E-Learning: Cardiotoxicity in Oncology Practice
ESMO E-Learning: Multimodular Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)
ESMO V-Learning: BRCA Across Tumour Types
ESMO E-Learning: Management of Cancer Associated Thrombosis
Meeting resources
The development of immunotherapies for mesothelioma
Presenter: Alessandra Curioni
Session: New indications in thoracic tumours (incl thymic and mesothelioma)
Resources:
Slides
Webcast
Bispecific NK engagers
Presenter: Eric Vivier
Session: NK cells biology and therapeutic opportunities, innate immunity, adaptive immunity
Resources:
Slides
Webcast
In vivo modulation of NKs
Presenter: Marcus Bosenberg
Session: NK cells biology and therapeutic opportunities, innate immunity, adaptive immunity
Resources:
Webcast
A multifaceted herpes simplex virus oncolytic immunotherapy platform
Presenter: Robert Coffin
Session: Direct intratumoural injection of immunotherapy
Resources:
Slides
Webcast